secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071370
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon Q1 net loss $6.5M; cash $124.9M; on track for BESTOW topline in Q4
-------------------------------------------------------------------------

- Net loss of $6.5M ($0.08/share) vs $23.6M loss in Q1 2024; adjusted net loss $16.6M vs $10.3M.
- Cash, equivalents and short-term investments $124.9M as of March 31, 2025; funds operations to end of 2026.
- R&D expenses $13.5M (incl. $1.0M SBC) vs $7.4M prior year; G&A $4.4M vs $3.5M.
- Tegoprubart used in second genetically modified pig kidney transplant at Mass General; patient discharged without dialysis.
- Topline Phase 2 BESTOW results on track for Q4 2025; interim Phase 1b data expected August 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017025071370/0000950170-25-071370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017025071370/eldn-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer